FDA Approves Libtayo in Combination with Chemotherapy for Patients with NSCLC Regardless of PD-L1 Status
On November 8th, 2022, the Food and Drug Administration (FDA) approved Libtayo (cemiplimab-rwlc) for treatment of non-small cell lung cancer where there are no changes in ALK, EGFR or ROS1 in combination with platinum doublet chemotherapy. The FDA based [...]